Supernus Pharmaceuticals (SUPN) Stock: Buy, Sell, or Hold?
SUPN - Supernus Pharmaceuticals, Inc.
$41.64
-0.05 (-0.12%)
▼
5d:
-5.3%
30d:
-13.01%
90d:
-8.58%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 03, 2026
Get Alerted When SUPN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: SUPN shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: SUPN shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$107.70
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$66.87
37.7% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SUPN is currently trading at $41.64, which is considered oversold relative to its 30-day fair value range of $43.29 to $47.69. From a valuation perspective, the stock is trading at a discount (Forward PE: 9.3) compared to its historical average (12.4). Remarkably, the market is currently pricing in an annual earnings decline of 9.0% over the next few years. This pessimistic expectation contrasts with the company's recent 11.1% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, SUPN is in a downtrend. The price is currently testing key support at $41.11. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SUPN scores 29/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $61.75 (+48.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SUPN is in a downtrend. The price is currently testing key support at $41.11. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SUPN scores 29/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $61.75 (+48.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$43.29 -
$47.69
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
65.4%
Protect Your Profits
Holding SUPN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (29/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 48.3% below Wall St target ($61.75)
- WARNING: Composite score 42/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$43.29 -
$47.69
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$2.97
(7.1%)
Support & Resistance Levels
Support Level
$41.11
Resistance Level
$45.05
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.34
Wall Street Target
$61.75
(+48.3%)
Revenue Growth (YoY)
32.4%
Earnings Growth (YoY)
11.1%
Profit Margin
-13.2%
Valuation Discount vs History
-9.0% cheaper
PE vs Historical
9.3 vs 12.4
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-9.0%
(market-implied from PE analysis)
1-Year Target
$37.89
(-9%)
2-Year Target
$34.48
(-17%)
3-Year Target
$31.38
(-25%)
3-Yr Target (if PE normalizes)
(PE: 9→12)
$41.68
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 73.9%)
$303.61
(+629%)
Base:
(SPY PE: 9.3, Growth: 73.9%)
$140.54
(+238%)
Bear:
(PE: 7.9, Growth: 73.9%)
$119.45
(+187%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.3 to 12.4
Stabilization Target:
$55.30
(+32.8%)
PE Expansion Potential:
+32.8%
Share & Embed Analysis
Last updated: September 13, 2026 6:25 AM ET
Data refreshes hourly during market hours. Next update: 7:25 AM
Data refreshes hourly during market hours. Next update: 7:25 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SUPN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Padmanabh P Bhatt
SELL
7250 shares
2026-03-18
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$212 | 60 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 70 BUY |
|
INDV
Indivior PLC Ordinary Sh… |
STRONG BUY
7 analysts |
$49 | 69 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 46 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 47 HOLD |
Advanced SUPN Option Strategies
Professional options setups generated by AI based on today's SUPN price and gamma walls.
